Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Family RESPOND: Defining the Genetic Basis of Prostate Cancer Risk in African American Families

Award Number: R01CA289492
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2025
PERIOD OF PERFORMANCE END DATE: 03/31/2030

Group Awards By:

View Award Description

Family RESPOND: Defining the Genetic Basis of Prostate Cancer Risk in African American Families - It has been estimated that more than 50% of prostate cancer (PCa) is inherited, with studies suggesting that both rare, moderate- to high-penetrant pathogenic variants (PVs) as well as more common variants of lower penetrance are important in explaining inherited susceptibility. Evidence to support this includes men with familial or hereditary PCa are at an increased risk for being diagnosed with PCa, and notably more likely to be diagnosed with aggressive clinical features. Rare mutations in DNA repair genes have been implicated in risk for multiple cancers including PCa, and screening for these mutations can determine eligibility for systemic therapies in the metastatic setting. Common genetic variants have also been demonstrated to play a critical role in PCa susceptibility, with polygenic risk scores (PRS) used to identify men with substantially elevated lifetime risks of overall PCa and aggressive disease. Unfortunately, studies investigating the genetic basis underlying familial aggregation of PCa in men of African ancestry have lagged behind those in men of European descent. While the PRS has shown consistent risk estimation across populations, we and others have found that the prevalence and spectrum of rare PVs in the African American (AA) population may be different than in populations of European ancestry. Integrating gene panel testing and PRS has the potential to provide men with PCa with more accurate information about genetically-informed treatment, risk for second cancers, and for unaffected relatives within the family, future cancer risk. The proposed investigation aims to define the genetic factors underlying familial PCa in AA men and to develop risk prediction models for AA men that incorporate the independent and combined effects of PRS, PVs and family history of PCa. To accomplish this, we will leverage existing genetic data for 24,000 unselected AA PCa cases and controls, which includes the RESPOND cohort, a landmark study of over 12,600 AA PCa cases identified through population-based registries from across the United States, including 7,500 with DNA and genetic information [whole-genome sequence (WGS) data], and 45% reporting a first- and/or second-degree FH of PCa. For this study, we will enroll additional eligible first- and second-degree affected and unaffected family members identified through RESPOND probands to study genetic factors that contribute to familial risk of PCa in AA men (Aim 1). Determine the relative contribution of germline variants to familial clustering of PCa and aggressive disease characteristics within unselected cases and controls (Aim 2) and in AA families in RESPOND (Aim 3). Simultaneously, we will develop and test a risk prediction tool for PCa specifically designed for AA men, that incorporates information on the joint impact of rare variants, PRS, and familial risk in AA families (Aim 4). Through this work, we aim to define the prevalence and spectrum of genetic variants in AA men that contribute to familial PCa and develop a PCa risk prediction tool specifically designed for AA men that can be used for counseling AA men about their risk and as a tool for future risk-stratified screening approaches.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $703,567 )
2026	2026	UNIVERSITY OF SOUTHERN CALIFORNIA	3720 S FLOWER ST FL 3	LOS ANGELES	CA	90033	LOS ANGELES	USA	Cancer Cause and Prevention Research	000	2	5/5/2026	NON-COMPETING CONTINUATION	$703,567
														Subtotal = $703,567

Issue Date FY: 2025 ( Subtotal = $704,882 )
2025	2025	UNIVERSITY OF SOUTHERN CALIFORNIA	3720 S FLOWER ST FL 3	LOS ANGELES	CA	90033	LOS ANGELES	USA	Cancer Cause and Prevention Research	000	1	3/31/2025	NEW	$704,882
														Subtotal = $704,882

Grand Total All Awards = $1,408,449

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Family RESPOND: Defining the Genetic Basis of Prostate Cancer Risk in African American Families

Award Number: R01CA289492

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2025

PERIOD OF PERFORMANCE END DATE: 03/31/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer